Linked Life Data

21880218

Source:http://linkedlifedata.com/resource/pubmed/id/21880218

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21880218rdf:typepubmed:Citationlld:pubmed
pubmed-article:21880218lifeskim:mentionsumls-concept:C0019169lld:lifeskim
pubmed-article:21880218lifeskim:mentionsumls-concept:C0037140lld:lifeskim
pubmed-article:21880218lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:21880218lifeskim:mentionsumls-concept:C0012634lld:lifeskim
pubmed-article:21880218lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:21880218lifeskim:mentionsumls-concept:C0027540lld:lifeskim
pubmed-article:21880218lifeskim:mentionsumls-concept:C1521761lld:lifeskim
pubmed-article:21880218lifeskim:mentionsumls-concept:C0936012lld:lifeskim
pubmed-article:21880218lifeskim:mentionsumls-concept:C0205262lld:lifeskim
pubmed-article:21880218lifeskim:mentionsumls-concept:C1514923lld:lifeskim
pubmed-article:21880218pubmed:issue2lld:pubmed
pubmed-article:21880218pubmed:dateCreated2011-9-1lld:pubmed
pubmed-article:21880218pubmed:abstractTextOne of the problems possibly related to the use of biological agents targeting tumor necrosis factor (TNF)-alpha is the increased risk of infections, including the activation of hepatitis B virus (HBV). HBV activation can occur in carriers of hepatitis B surface antigen (HBsAg), but the risk may also involve the HBsAg-negative (anti-HBc ± anti-HBs) occult carriers. Precise data on the safety of anti-TNF and/or other immunosuppressive drugs in HBV occult carriers are not available. We performed a retrospective analysis of 62 psoriatic patients with occult HBV infection treated with anti-TNF biological agents over a period of approximately 4 years: 44 subjects were treated with etanercept, 8 with infliximab and 10 with adalimumab. During the observational treatment period, no signs of HBV activation were observed. Only in one patient the reappearance of HBsAg, without detectable HBV-DNA, was noted before retreatment with etanercept and after 10 months from discontinuation of the previous course. In this patient etanercept was re-administered in association with lamivudine without any adverse event. Our results suggest the overall safety of treatment with anti-TNF drugs in HBV occult carriers, although a careful and constant monitoring of virological markers is required in such patients during treatment with anti-TNF drugs in order to have an early recognition of viral reactivation.lld:pubmed
pubmed-article:21880218pubmed:languageenglld:pubmed
pubmed-article:21880218pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21880218pubmed:citationSubsetIMlld:pubmed
pubmed-article:21880218pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21880218pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21880218pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21880218pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21880218pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21880218pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21880218pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21880218pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21880218pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21880218pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21880218pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21880218pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21880218pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21880218pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21880218pubmed:statusMEDLINElld:pubmed
pubmed-article:21880218pubmed:issn0393-974Xlld:pubmed
pubmed-article:21880218pubmed:authorpubmed-author:VenaG AGAlld:pubmed
pubmed-article:21880218pubmed:authorpubmed-author:Di LeoAAlld:pubmed
pubmed-article:21880218pubmed:authorpubmed-author:MastrandreaVVlld:pubmed
pubmed-article:21880218pubmed:authorpubmed-author:LoconsoleFFlld:pubmed
pubmed-article:21880218pubmed:authorpubmed-author:CassanoNNlld:pubmed
pubmed-article:21880218pubmed:authorpubmed-author:PrincipiMMlld:pubmed
pubmed-article:21880218pubmed:authorpubmed-author:De TullioNNlld:pubmed
pubmed-article:21880218pubmed:issnTypePrintlld:pubmed
pubmed-article:21880218pubmed:volume25lld:pubmed
pubmed-article:21880218pubmed:ownerNLMlld:pubmed
pubmed-article:21880218pubmed:authorsCompleteYlld:pubmed
pubmed-article:21880218pubmed:pagination285-9lld:pubmed
pubmed-article:21880218pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:21880218pubmed:meshHeadingpubmed-meshheading:21880218...lld:pubmed
pubmed-article:21880218pubmed:meshHeadingpubmed-meshheading:21880218...lld:pubmed
pubmed-article:21880218pubmed:meshHeadingpubmed-meshheading:21880218...lld:pubmed
pubmed-article:21880218pubmed:meshHeadingpubmed-meshheading:21880218...lld:pubmed
pubmed-article:21880218pubmed:meshHeadingpubmed-meshheading:21880218...lld:pubmed
pubmed-article:21880218pubmed:meshHeadingpubmed-meshheading:21880218...lld:pubmed
pubmed-article:21880218pubmed:meshHeadingpubmed-meshheading:21880218...lld:pubmed
pubmed-article:21880218pubmed:meshHeadingpubmed-meshheading:21880218...lld:pubmed
pubmed-article:21880218pubmed:meshHeadingpubmed-meshheading:21880218...lld:pubmed
pubmed-article:21880218pubmed:meshHeadingpubmed-meshheading:21880218...lld:pubmed
pubmed-article:21880218pubmed:meshHeadingpubmed-meshheading:21880218...lld:pubmed
pubmed-article:21880218pubmed:meshHeadingpubmed-meshheading:21880218...lld:pubmed
pubmed-article:21880218pubmed:meshHeadingpubmed-meshheading:21880218...lld:pubmed
pubmed-article:21880218pubmed:meshHeadingpubmed-meshheading:21880218...lld:pubmed
pubmed-article:21880218pubmed:meshHeadingpubmed-meshheading:21880218...lld:pubmed
pubmed-article:21880218pubmed:meshHeadingpubmed-meshheading:21880218...lld:pubmed
pubmed-article:21880218pubmed:meshHeadingpubmed-meshheading:21880218...lld:pubmed
pubmed-article:21880218pubmed:meshHeadingpubmed-meshheading:21880218...lld:pubmed
pubmed-article:21880218pubmed:meshHeadingpubmed-meshheading:21880218...lld:pubmed
pubmed-article:21880218pubmed:meshHeadingpubmed-meshheading:21880218...lld:pubmed
pubmed-article:21880218pubmed:meshHeadingpubmed-meshheading:21880218...lld:pubmed
pubmed-article:21880218pubmed:meshHeadingpubmed-meshheading:21880218...lld:pubmed
pubmed-article:21880218pubmed:meshHeadingpubmed-meshheading:21880218...lld:pubmed
pubmed-article:21880218pubmed:articleTitleAnti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease.lld:pubmed
pubmed-article:21880218pubmed:publicationTypeLetterlld:pubmed